PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC)

被引：0
作者：
Tannir, Nizar M.
Agarwal, Neeraj
Pal, Sumanta K.
Cho, Daniel C.
Formiga, Maria
Guo, Jun
George, Daniel J.
Tagliaferri, Mary Ann
Singel, Stina Mui
O'Keeffe, Bridget A.
Hannah, Alison L.
Balbas, Minna
Penkov, Konstantin
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] NYU, Perlmutter Canc Ctr, Langone Hlth, New York, NY USA
[5] AC Camargo Canc Ctr, Sao Paulo, Brazil
[6] Peking Univ, Canc Hosp & Inst, Beijing Shi, Peoples R China
[7] Duke Univ, Sch Med, Durham, NC USA
[8] Nektar Therapeut, San Francisco, CA USA
[9] Private Med Inst Euromedserv, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS763
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
    Albiges, L.
    Rini, B. I.
    Peltola, K.
    Oria, G. A. De Velasco
    Burotto, M.
    Rodriguez, C. Suarez
    Ghatalia, P.
    Iacovelli, R.
    Lam, E. T.
    Verzoni, E.
    Gumus, M.
    Stadler, W. M.
    Kollmannsberger, C. K.
    Melichar, B.
    Venugopal, B.
    Wang, A.
    Perini, R.
    Vickery, D.
    Powles, T. B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1329 - S1330
  • [42] INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
  • [43] A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
    Kiyota, Naomi
    Hasegawa, Yasuhisa
    Takahashi, Shunji
    Yokota, Tomoya
    Yen, Chia-Jui
    Iwae, Shigemichi
    Shimizu, Yasushi
    Hong, Ruey-Long
    Goto, Masahiro
    Kang, Jin-Hyoung
    Li, Wing Sum Kenneth
    Ferris, Robert L.
    Gillison, Maura
    Namba, Yoshinobu
    Monga, Manish
    Lynch, Mark
    Tahara, Makoto
    ORAL ONCOLOGY, 2017, 73 : 138 - 146
  • [44] PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
    Grivas, Petros
    Van der Heijden, Michiel Simon
    Necchi, Andrea
    Siefker-Radtke, Arlene O.
    Cutuli, Hernan
    Qureshi, Anila H.
    Kreiser, Stephanie
    Hodari, Moana
    Ravimohan, Shruthi
    Zakharia, Yousef
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [45] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
    Rini, Brian I.
    Pal, Sumanta K.
    Escudier, Bernard
    Atkins, Michael B.
    Hutson, Thomas E.
    Porta, Camillo
    Verzoni, Elena
    Needle, Michael N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [47] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901)
    Waller, C. F.
    Galsky, M. D.
    Powles, T.
    van der Heijden, M. S.
    Li, S.
    Hennicken, D.
    Sonpavde, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 325
  • [48] Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214
    Gruenwald, Viktor
    Choueiri, Toni K.
    Rini, Brian I.
    Powles, Thomas
    George, Saby
    Grimm, Marc-Oliver
    Mchenry, M. Brent
    Maurer, Matthew
    Motzer, Robert J.
    Hammers, Hans J.
    Tannir, Nizar M.
    Albiges, Laurence
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 74 - 75
  • [49] First-line Treatment for advanced Renal Cell Carcinoma A Phase 3, open-label, randomized Study of Atezolizumab (Anti-PD-L1-Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with untreated advanced Renal Cell Carcinoma ("IMmotion") AN 37/15 of AUO
    Rexer, H.
    Doehn, C.
    UROLOGE, 2016, 55 (09): : 1242 - 1243
  • [50] Early Completion of Phase-III-Study CheckMate-214: Nivolumab in Combination with Ipilimumab shows an Overall Survival Benefit in Patients with previously untreated advanced or metastatic Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (11)
12345